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A B S T R A C T
Background: The feasibility and efﬁcacy of simultaneous percutaneous treatment of secundum type
atrial septal defect (ASD) combined with pulmonary valve stenosis (PS) have not been proved.
Objective: To evaluate the safety and efﬁcacy on the clinical beneﬁt of simultaneous percutaneous
correction of these two pathologies under local anesthesia and without transesophageal echocardiog-
raphy guidance.
Methods: Transpulmonary gradient, functional status, pulmonary regurgitation (PR), and tricuspid
regurgitation (TR) were studied in 35 patients undergoing percutaneous balloon pulmonary
valvuloplasty and ASD closure from March 2004 to July 2012. All patients were followed up until
January 2013, an average of 39 months.
Results: According to color Doppler transthoracic echocardiography (TTE) before the intervention, the
ASD defect size and transpulmonary gradient were 17  8.4 mm and 88  37.8 mmHg, respectively. Post-
interventionally, the peak-to-peak transpulmonary gradient decreased from 77  37.6 mmHg to
20  16.2 mmHg (p < 0.001) and the ASD occluder size was 23  10.5 mm. In all those patients, there
was no residual shunt detected, andmoderate and severe TR decreased from 45.7% (16/35) and 20% (7/35) to
8.6% (3/35) and 5.7% (2/35) before and after intervention detected by TTE, respectively. Eight patients had
mild PR after procedure and two of them recovered at 6 months and no patient encountered severe adverse
events at the latest follow-up.
Conclusion: Simultaneous percutaneous corrections of ASD combined with PS are feasible, safe, and
effective with satisfactory results.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Pulmonary valve stenosis (PS) and secundum type atrial septal
defect (ASD) are common forms of congenital heart disease. SinceDOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2014.06.002.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsthe ﬁrst successful clinical application and report in 1982 [1],
percutaneous balloon pulmonary valvuloplasty (PBPV) has
replaced surgery as the initial treatment of choice in patients of
all ages with pure PS [2–5]. Nowadays, the transcatheter closure of
ASDs, using various percutaneous occlusion devices in both
children and adults, offers an alternative to surgical treatment
due to its better clinical and follow-up results [6–9]. However, the
association of PS with ASD is relatively rare, and successful
transcatheter correction was reported mainly as anecdotal single
case reports [10–15]. The feasibility and efﬁcacy of simultaneous
percutaneous treatment of the two pathologies have not been
proved with large series of successful cases. The aim of the present
study was, therefore, to evaluate the effects of simultaneous
transcatheter corrections of ASD combined with PS on transvalvarreserved.
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tricuspid regurgitation (TR) at intervention in an unselected cohort
of Chinese patients.
Methods
Patient population
The study population consisted of 35 consecutive patients who
underwent simultaneous transcatheter ASD closure with the
SHSMA occlude (Shape Memory Alloy Ltd, Shanghai, China) and
PBPVwith the Inoue balloon catheter (Toray Industries, Inc., Tokyo,
Japan) or Cristal balloon (BALT Extrusion, Montmorency, France).
Indications for ASD closure were (1) age  3 years; (2) 5 mm  the
maximum diameter  38 mm by transthoracic echocardiography
(TTE), irrespective of the presence of symptoms. Our indications for
PBPVwere (1) the peak-to-peak catheter systolic pressure gradient
across the pulmonary valve (PV) of >40 mmHg regardless of
symptoms; (2) no obvious right ventricular outﬂow tract
obstruction and pulmonary valve ring and right ventricular
dysplasia.
During the study period, transcatheter combined procedure
was attempted in 36 patients, but 1 patient did not undergo PBPV
because of unqualiﬁed gradient detected by catheter. Transcath-
eter ASD closure was not attempted in patients with inadequate
defect morphology or ostium primum defect detected by TTE. For
these reasons, three patients referred to our institution had
surgical ASD repair, pulmonary valve dissection, and tricuspid
valvuloplasty during the study period. All patients underwent
clinical examination, chest X-ray, electrocardiogram (ECG), and
TTE before the procedure. Before intervention, informed written
consent was obtained from all patients or their parents. The study
was approved by the ethics committee of Changhai Hospital, and
was carried out in accordance with the Declaration of Helsinki
(1996) and all relevant Chinese laws.
Echocardiography
A comprehensive TTE, including M-mode, two-dimensional,
and color Doppler echocardiography was routinely performed
before intervention and at each follow-up visit in all patients.
Transvalvar gradientwas estimated from the blood ﬂow velocity in
pulmonary valve. The severity of TR was assessed on the basis of
the spatial distribution of the central regurgitant jet within the
right atrium by color Doppler ﬂow mapping. TR was graded as
trivial if the jet area was<1 cm2, mild if it was<5 cm2, moderate if
it was 5–10 cm2, and severe if it was>10 cm2 [16]. An average of at
least ﬁve determinations of each echocardiographic variable were
analyzed. The quantitative and categorical data are presented as
the mean  standard deviation and as percentages, respectively.
Combined ASD closure and pulmonary valve dilatation
Wahl et al. [12] ﬁrst described the procedure under local
anesthesia without TEE guidance, a technique also used in the
adult patients of the current report. The location, size, and
relationship of ASD with the surrounding tissue (atrioventricular
valve, superior and inferior vena cava, etc.) were assessed using
TTE in three standard views (parasternal/cardiac apical four-
chamber view, inferior xiphoid process couple atrium, and great
artery minor axial views) before the procedure. The PBPV was
performed ﬁrst, followed by the release of ASD occluder. The
femoral vein was accessed, and intravenous heparin (100 IU/kg)
was administered. A multifunction catheter was introduced into
the right ventricle and pulmonary artery and the maximum
transvalvar gradient was obtained. A pigtail catheter was placed inthe right ventricle and lateral angiograms were performed to
measure the PV annulus diameters and assess the right ventricle
and valve anatomy. The angiographic catheter was replaced with
the multifunction catheter, which was manipulated in either the
left or the right pulmonary arteries. An exchange guide wire was
placed in the peripheral pulmonary artery and the multifunction
catheter was replaced with the Inoue dilatation balloon or BALT
balloon. The balloon was centered across the valve annulus in the
lateral view and rapidly inﬂated by hand with diluted contrast
material until the disappearance of the waist (Fig. 1 A–C). The
deﬂated balloonwas then removedwhile keeping the guidewire in
the pulmonary artery. The guide wire permitted the repositioning
of an end-hole catheter into the distal pulmonary artery for
pressure measurements. Then, transcatheter ASD closure was
carried out. After routine cardiac catheterization with oxymetric
and pressure recordings (right ventricular and pulmonary artery
pressure), a transport sheath (10–14F) was advanced over an
exchange guidewire into the left atrium. The device (4–8 mm
larger than the native diameter detected by TTE) was inserted into
the sheath and carefully deployed. Once the selected device was
implanted, and before releasing it, a new TTE evaluation in three
standard views mentioned above assessed the adequacy of its
position, the persistence of residual shunt, and the stability of the
devicewithin the septum. Careful pull and pushmovement tests of
the union between the anchored device and the cannula permitted
us to evaluate the possible instability of the device. After the proper
size and position of the occluder was conﬁrmed and any effect on
tricuspid valve function was excluded by TTE, the occluder was
completely released (Fig. 1D–F).
The following pressures were recorded before and immediately
after PBPV: right ventricular systolic pressure (RVSP), right
ventricular diastolic pressure (RVDP), right ventricular mean
pressure (RVMP), pulmonary artery systolic pressure (PASP),
pulmonary artery diastolic pressure (PADP), pulmonary artery
mean pressure (PAMP), and RV to PA systolic pressure gradient.
Follow-up
Aspirin therapy (3–5 mg/kg/day) was administered for 6
months to all patients. Intravenous heparin was administered
intraprocedurally. Theywere studied clinically and by ECG and TTE
at discharge, 1, 3, 6, 12 months, and annually thereafter. Particular
care was taken to determine the functional status and to obtain
information regarding symptom development or any complica-
tions.
Statistical analysis
All continuous variables are expressed as mean  standard
deviation (SD) or median with range as appropriate, and discrete
variables are presented as frequencies and/or percentages. We used
SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA) for the statistical
analysis. Comparisons of data were performed using the Student’s
t-test or Wilcoxon rank-sum test (continuous variables) and the chi-
square test or Fisher’s exact test (categorical variables) as appropriate.
All tests were two-sided, and p-values <0.05 were considered as
indicating statistical signiﬁcance.
Results
Baseline characteristics
Baseline patient characteristics are shown in Table 1. Prior to
intervention, 17 patients were symptomatic. Limited exercise
capacity and shortness of breath were the most frequently
reported symptoms. Moderate TR and severe TR were present in
[(Fig._1)TD$FIG]
Fig. 1. Successful correction of pulmonary valve stenosis and atrial septal defect after percutaneous balloon valvuloplasty and defect occluder in a 38-year-old male patient.
(A) Lateral right ventricular angiogramobtained before balloon valvuloplasty shows narrowblood jet through the severe stenotic pulmonary valve. (B) Inoue balloon (26 mm)
being inﬂated after crossing the stenotic valve. (C) Successful inﬂation of the balloon with near disappearance of the waist in an adult with severe pulmonary valve stenosis.
(D) The nitinol guidewire was introduced to the left superior pulmonary vein. (E) A transport sheath (10 French) was advanced over the exchange guidewire into the left
atrium and the occluder was inserted into the sheath. (F) A 14-mm SHSMA atrial septal defect occluder was implanted (LAO 458 + CRAN 258).
X.-D. Xu et al. / Journal of Cardiology 65 (2015) 32–363416 (45.7%) and 7 (20%) patients, respectively (Fig. 2). The
transvalvar gradient obtained by echocardiography in the patients
before anesthesia was on average 11 mmHg higher than the
invasively measured pressure during local anesthesia.Table 1
Patient characteristics at study entry (median with range).
Patients (n) 35
Gender (female), n (%) 22 (62.9)
Age (years) 32 (3–69)
Echocardiographic data
ASD size (mm) 16 (5–38)
Transpulmonary gradient 78 (46–222)
Moderate TR, n (%) 16 (45.8)
Severe TR, n (%) 7 (20)
Clinical data
NYHA I, n (%) 18
NYHA II, n (%) 12
NYHA III, n (%) 5
NYHA IV, n (%) 0
Catheterization
RV systolic pressure (mmHg) 95 (67–233)
RV mean pressure (mmHg) 32 (21–105)
RV diastolic pressure (mmHg) 2 (-10–23)
PA systolic pressure (mmHg) 27 (12–43)
PA mean pressure (mmHg) 19 (7–31)
PA diastolic pressure (mmHg) 12 (4–25)
Peak-to-peak gradient 70 (40–199)
Qp/Qs 1.4 (0.7–2.1)
Mean size of the ASD occluders (mm) 24 (8–48)
Fluoroscopy time (min) 6 (4–12)
Procedure time (min) 43 (36–70)
Follow-up time (months) 35 (6–102)
Data are presented as mean with range where appropriate. ASD, atrial septal
defect; TR, tricuspid regurgitation; NYHA, New York Heart Association
functional class; Qp:Qs, pulmonary to systemic ﬂow ratio; PA, pulmonary
artery; RV, right ventricular.Procedural data and complications
The transcatheter interventional procedures were successful in
all patients in the present study. A total of 35 SHSMAoccluderswere
implanted. The size of the ASD diameters ranged from 5 to 38mm
(median 16mm), detected by TTE, and the diameters of ASD
occluders ranged from 8 to 48 mm (median 24mm). No residual
shunt was detected by TTE in all patients. The peak-to-peak
transvalvar gradient decreased from 77 37.6 mmHg before to
20 16.2 mmHgafter the combinedprocedure (4patients less than12
years by BALT balloon and another 31 patients by Inoue balloon, Fig. 3,
p < 0.001). The pulmonary valve annulus was measured from lateral
view of right ventricular angiogram. The BALT balloon diameters used
are 1.2 times of the pulmonary valve annulus diameter and Inoue
balloon diameters are 24–26 mm. Moderate and severe TR decreased
[(Fig._2)TD$FIG]
Fig. 2. Tricuspid regurgitation before (pre) and after (post) percutaneous balloon
pulmonary valvuloplasty and atrial septal defect closure.
[(Fig._3)TD$FIG]
Fig. 3. The transpulmonary gradient was signiﬁcantly decreased after the combined
procedure.
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after intervention detected by TTE, respectively. Symptoms were
present in 49% (17/35) of the patients before and in 17% (6/35) after the
procedure. Most symptomatic patients were accompanied by signiﬁ-
cantTR, regardlessofwhether theywerepreoperativeorpostoperative.
Eight patients had mild pulmonary regurgitation after procedure and
no other major procedural complications occurred. Spontaneously
resolving supraventricular arrhythmias were common during the
procedure. At the end of the procedure, one patient had new atrial
tachycardia and converted spontaneously to sinus rhythm. Intrapro-
cedural pressure measurement revealed slight decreased right
ventricular pressure after PBPV in two patients. They underwent
successful closurewithout signs of right heart failure eventually. Atrial
ﬁbrillation was recorded in two patients within 24 h after the
procedure. One of these spontaneously converted to sinus rhythm,
whereas another underwent successful medical conversion (propafe-
none, 70 mg). Two patients developed transient complete right bundle
branch block and recovered before discharge.
Follow-up data
The mean follow-up was 39  29.9 months and early follow-up
data (6months)were available for all patients. Two patientswith pre-
existing persistent atrial ﬁbrillation remained in atrial ﬁbrillation. In
addition, one patient who had paroxysmal atrial ﬁbrillation at entry
developed persistent atrial ﬁbrillation at follow-up. In all those
patients having been implanted with ASD occluders, there was no
residual shunt detected by TTE and all devices were in their
appropriate positions. No patients had encountered serious compli-
cations, including atrioventricular conduction block, thromboembo-
lism, erosion, and deaths during follow-up.
Regression of transvalvar gradient
Transvalvar gradient decreased from 88 37.8 mmHg before to
29 10.5 mmHg on day 3 and 26 6.1 mmHg at 3 months and
25 4.4 mmHgat6monthsafter procedure (p < 0.01)detectedbyTTE.
Tricuspid regurgitation and pulmonary regurgitation
After ASD closure and PBPV, the degree of TR decreased. Only
two of originally seven patients still had severe TR and three
(originally 16) hadmoderate TR. They also improvedwith regard tofunctional status. Of the seven patients with originally severe TR,
two were asymptomatic and four were in New York Heart
Association (NYHA) class II and one in NYHA class III after the
procedure. Interestingly, one patient with severe TR at discharge
had a mild to moderate regurgitation at 1-year TTE follow-up. No
patient had emerging or worsening TR. After the procedure, eight
patients had mild pulmonary regurgitation detected by TTE. Two
patients recovered at 6-month follow-up and another six patients
remained in mild regurgitation.
Functional status
Symptomatic improvement was observed in most of the
patients. After 3 months, one patient remained in NYHA class III
and two patients in NYHA class II, and the other patients in NYHA
class I. These three symptomatic patients were suffering from
signiﬁcant TR.
Discussion
PS may be valvular, infundibular, or supravalvular and is
generally of the valvular type when associated with ASD. Themain
pathological change of this disease is obstruction of the outﬂow
tract of the right ventricle. When the two conditions are present
simultaneously, signiﬁcant left-to-right shunt is often prevented
by the outﬂow obstruction, which protects the pulmonary vascular
bed without prematurely damaging until adulthood. PBPV has
become the initial choice for the treatment of PS in all age groups,
even neonates, given the low risk and the excellent early and late
results. Therapeutic options for ASD depend on the location and
size of the defect [17]. Transcatheter procedure has certain
limitations, since only secundum type ASD generally less than
38 mm in diameter can be treated in this way. All small-diameter
ASDs that cause no hemodynamic effects are excluded from any
type of intervention, except in patients who present with
paradoxical embolism, irrespective of the diameter of the ASD.
However, simultaneous percutaneous treatment of the two
pathologies is relatively rare. This report describes the largest
hitherto published experience including mid-term follow-up of
simultaneous correction of PS and ASD with special emphasis on
transvalvar gradient, functional status, PR, and TR.
It is crucial to choose a correct and reasonable order to ensure
the safety of transcatheter interventional therapy. But it is
controversial to decide the procedure order. Treating the ASD
ﬁrst should eliminate the left-to-right shunt and thus also the right
ventricle volumes overload and possibly lower the pressure
gradient across the pulmonary valve, enabling one to reassess
the severity of pulmonary stenosis. On the other hand, PBPV ﬁrst
lowers the peri-procedural risk of ASD occluder device dislodge-
ment. We paid more attention to the latter and signiﬁcant decline
of transvalvar gradient had not been observed in most of the
patients after ASD closure. Thus, the PBPVwas performed ﬁrst, and
then the ASD closure. The indications of same period ASD closure
depend on the effects of PBPV and the right ventricular compliance.
Full inﬂation of the balloon, improvement of symptoms and
cyanosis, increase of arterial oxygen saturation, decrease of right-
to-left shunt and TR detected by TTE and no severe right
ventricular outﬂow tract obstruction were suitable for the ASD
closure simultaneously. In our report, simultaneous ASD closure
and PBPV were performed in all patients and no one encountered
serious right ventricular outﬂow tract spasm.
The Inoue balloon, which is shorter than other balloons, was
chosen for patients who were older than 12 years, were more than
30 kg and the PV annulus was greater than 24mm. The shorter
balloon reduced the ﬁlled time and the opportunity to squeeze into
right ventricular outﬂow tract, resulting in spasm, rise of right
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ventricular outﬂow tract was irritated, the following ASD closure
should be ceased and beta-blockers should be given. About 3months
later, theASDclosurecouldbeperformedwhenthe spasmis resolved.
Varying degrees of TR were present in almost all of these
patients. Because TR cannot be repaired by an interventional
approach, some cardiologists believe that these patients should be
treated by surgery, including ASD repair, pulmonary valve
dissection, and tricuspid valvuloplasty. But our results revealed
that TR was mainly related to right ventricular volume overload
attributed to increase of left-to-right and blocking of the
pulmonary artery forward blood. After the combined procedure,
TR reduced signiﬁcantly in most of the patients, regardless of
whether it was moderate or severe. These results reveal that TR is
functional and will recover after transcatheter ASD closure and
PBPV in most patients. Deterioration of right ventricular compli-
ance is one of the most important reasons to reduce cardiac
function reserve and activity tolerance. The cardiopulmonary
bypass can reduce right ventricular compliance andmaybe not the
preferred approach. Moreover, transcatheter intervention can be
used as a palliative means before surgery.
Ultrasound plays an important role in interventional treatment
of congenital heart diseases. TTEwasmainly observed in the apical
four-chamber, parasternal short-axis, and subxiphoid couple
atrium view in the ASD closure. The distances from anterior-
inferior and posterior-superior edge of defect to the root of mitral
valve anterior leaf were observed in the apical four-chamber view.
The rim of atrial defect at aorta side and posterior edge were
observed in parasternal short-axis view and the anteroposterior
diameter of ASD can be determined. The margins next to the
superior vena cava and inferior vena cava were observed in
subxiphoid couple atrium view and the vertical diameter of ASD
can been determined. Through these three main sections, the
whole picture of ASD can be shown clearly. Our experience has
shown that TTE can fully meet the need of the procedure and
follow-up. The gradient had a downward trend in follow-ups,
suggesting alleviation of spasm of infundibular muscle, which
coincided with the report of Beghetti and colleagues [18].
Limitations
Our study demonstrated positive efﬁcacy and safety of
simultaneous percutaneous intervention of ASD and PS; neverthe-
less, it had some limitations. Firstly, it was a retrospective, non-
randomized study in a single center in China. The experience may
not be universally representative. Secondly, follow-up in our study
was short and a few patients were not seen after the 6th month
postoperative clinic visit.
Conclusion
Our results demonstrate that the simultaneous interventional
treatment of PS and ASD is a safe and effective method. Good
clinical results can be achieved as long as strict indications and
contraindications were executed.Conﬂicts of interest
The authors declare that there are no conﬂicts of interest.
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